ArticleAddiction (Abingdon, England)2019
Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Article in Addiction (Abingdon, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study.Pain medicine (Malden, Mass.) · 2026Pooled it
- The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.Addiction science & clinical practice · 2021Pooled it
- Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs.Drug and alcohol dependence · 2020Trial
- Cross sectional analysis of an addiction consultation service, substance co-use patterns, and receipt of medications for opioid use disorder during hospitalization.Journal of substance use and addiction treatment · 2024Article
- Impact of an intervention to implement provision of opioid use disorder medication among patients with and without co-occurring substance use disorders.Journal of substance use and addiction treatment · 2023Article
- Integrating Opioid Use Disorder Treatment Into Primary Care Settings.JAMA network open · 2023Article
- Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.Addiction science & clinical practice · 2023Article
- Augmenting project ECHO for opioid use disorder with data-informed quality improvement.Addiction science & clinical practice · 2023Article
- Ambivalence and Stigma Beliefs About Medication Treatment Among Young Adults With Opioid Use Disorder: A Qualitative Exploration of Young Adults' Perspectives.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2023Article
- Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.Journal of substance abuse treatment · 2022Review
- Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.Substance abuse treatment, prevention, and policy · 2021Article
- An Exploratory Study of Sex and Gender Differences in Demographic, Psychosocial, Clinical, and Substance Use Treatment Characteristics of Patients in Outpatient Opioid Use Disorder Treatment with Buprenorphine.Translational issues in psychological science · 2021Article
- Commentary on Hill et al.: Breaking down barriers-increasing access to lifesaving opioid use disorder medications to save lives.Addiction (Abingdon, England) · 2021Article
- "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.Substance use & misuse · 2021Article
- Opioid knowledge and perceptions among Hispanic/Latino residents in Los Angeles.Substance abuse · 2021Article
- Do Sex Differences Among Adults With Opioid Use Disorder Reflect Sex-specific Vulnerabilities? A Study of Behavioral Health Comorbidities, Pain, and Quality of Life.Journal of addiction medicine · 2020Article
- Trends in the Use of Buprenorphine in US Emergency Departments, 2002-2017.JAMA network open · 2020Article
- Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others.Health affairs (Project Hope) · 2020Article
- Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.Journal of substance abuse treatment · 2020Article
- Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.Drug and alcohol dependence · 2020Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsOpioid use disorder (OUD) remains a serious public health issue, and treating adults with OUD is a major priority in the United States. Little is known about trends in the diagnosis of OUD and in buprenorphine prescribing by physicians in office-based medical practices. We sought to characterize OUD diagnoses and buprenorphine prescribing among adults with OUD in the United States between 2006 and 2015. DESIGN AND SETTINGS: We used a repeated cross-sectional design, based on data from the 2006-15 National Ambulatory Medical Care Surveys that surveyed nationally representative samples of office-based out-patient physician visits.
participantsAdult patients aged 18 years or older with a diagnosis of OUD (n = 1034 unweighted) were included. MEASUREMENTS: Buprenorphine prescribing was defined by whether visits involved buprenorphine or buprenorphine-naloxone, or not. We also examined other covariates (e.g. age, gender, race and psychiatric comorbidities).
findingsWe observed an almost tripling of the diagnosis of OUD from 0.14% in 2006-10 to 0.38% in 2011-15 in office-based medical practices (P < 0.001). Among adults diagnosed with OUD, buprenorphine prescribing increased from 56.1% in 2006-10 to 73.6% in 2011-15 (P = 0.126). Adults with OUD were less likely to receive buprenorphine prescriptions if they were Hispanic [adjusted odds ratio (aOR) = 0.26; 95% confidence interval (CI) = 0.11, 0.60], had Medicaid insurance (aOR = 0.27; 95% CI = 0.10, 0.74) or were diagnosed with other psychiatric disorders (aOR = 0.45; 95% CI = 0.25, 0.83) or substance use disorders (aOR = 0.19; 95% CI = 0.09, 0.41).
conclusionsIn office-based medical practices in the United States, diagnoses for opioid use disorder and buprenorphine prescriptions for adults with opioid use disorder increased from 0.14 and 56.1%, respectively, in 2006-10 to 0.38 and 73.6% in 2011-15.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.